Genentech

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases offering training for it.

UNC Charlotte researchers are contributing to pioneering breakthroughs in cancer therapeutics, communicable disease forecasting and prevention, optical applications for health care, and use of AI and other innovative computational tools — and more.

This new approach, powered by a specialised protein large language model, predicts the most effective protein variants while using 99% less data than traditional methods.

AI-driven genomics startups leverage technology to analyze genetic data, predict predispositions, and offer personalized health recommendations.

We recently published a list of 10 AI News and Ratings Too Important to Miss. In this article, we are going to take a look at where GE HealthCare Technologies Inc. (NASDAQ:GEHC) stands against other AI news and ratings too important to miss.

Tevogen Bio has expanded its partnership with Microsoft, aiming to further its AI-centred collaboration and advance its predictive precision T-cell targeting technology, PredicTcell.

SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will transform medicine and research.